<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35490444</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>23</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1872-8421</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>367</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>15</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of neuroimmunology</Title>
          <ISOAbbreviation>J Neuroimmunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Changes in ganglioside antibody positivity rates during the COVID-19 pandemic.</ArticleTitle>
        <Pagination>
          <StartPage>577877</StartPage>
          <MedlinePgn>577877</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jneuroim.2022.577877</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0165-5728(22)00072-8</ELocationID>
        <Abstract>
          <AbstractText>Reports suggested an association between SARS-CoV-2 infection and GBS, but subsequent studies produced conflicting results regarding the incidence of GBS during the pandemic. This study assessed positivity rates for GQ1b, GM-1, GD1a, and GD1b for tests performed January 2016, through March 2021, at a national laboratory. Relative to pre-pandemic levels, positivity rates during the pandemic declined by 61% for GQ1b and 24% for GM-1, while unchanged for GD1a and GD1b. These findings suggest heterogeneity with positivity rates of GBS-associated ganglioside antibodies during the COVID-19 pandemic. Mitigation strategies during the pandemic may have reduced the frequency of certain forms of GBS.</AbstractText>
          <CopyrightInformation>Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Racke</LastName>
            <ForeName>Michael K</ForeName>
            <Initials>MK</Initials>
            <AffiliationInfo>
              <Affiliation>Quest Diagnostics, 500 Plaza Drive, Secaucus, NJ 07094, USA. Electronic address: Michael.K.Racke@QuestDiagnostics.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Niles</LastName>
            <ForeName>Justin K</ForeName>
            <Initials>JK</Initials>
            <AffiliationInfo>
              <Affiliation>Quest Diagnostics, 500 Plaza Drive, Secaucus, NJ 07094, USA. Electronic address: Justin.K.Niles@QuestDiagnostics.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lorenz</LastName>
            <ForeName>Raymond A</ForeName>
            <Initials>RA</Initials>
            <AffiliationInfo>
              <Affiliation>Quest Diagnostics, 500 Plaza Drive, Secaucus, NJ 07094, USA. Electronic address: Raymond.A.Lorenz@QuestDiagnostics.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kaufman</LastName>
            <ForeName>Harvey W</ForeName>
            <Initials>HW</Initials>
            <AffiliationInfo>
              <Affiliation>Quest Diagnostics, 500 Plaza Drive, Secaucus, NJ 07094, USA. Electronic address: Harvey.W.Kaufman@QuestDiagnostics.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Neuroimmunol</MedlineTA>
        <NlmUniqueID>8109498</NlmUniqueID>
        <ISSNLinking>0165-5728</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005732">Gangliosides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>37758-47-7</RegistryNumber>
          <NameOfSubstance UI="D005677">G(M1) Ganglioside</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName>
          <QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005677" MajorTopicYN="N">G(M1) Ganglioside</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005732" MajorTopicYN="N">Gangliosides</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="Y">Guillain-Barre Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Antiganglioside antibodies</Keyword>
        <Keyword MajorTopicYN="Y">COVID-19</Keyword>
        <Keyword MajorTopicYN="Y">Guillain-Barré syndrome</Keyword>
        <Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>7</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>1</Day>
          <Hour>18</Hour>
          <Minute>13</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35490444</ArticleId>
        <ArticleId IdType="pmc">PMC9023361</ArticleId>
        <ArticleId IdType="doi">10.1016/j.jneuroim.2022.577877</ArticleId>
        <ArticleId IdType="pii">S0165-5728(22)00072-8</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Abu-Rumeileh S., Abdelhak A., Foschi M., Tumani H., Otto M. Guillain-Barre syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. J. Neurol. 2021;268:1133–1170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7445716</ArticleId>
            <ArticleId IdType="pubmed">32840686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Allen C.M., Ransamy S., Tarr A.W., et al.  Guillain-Barre variant occurring after SARS-CoV-2 vaccination. Ann. Neurol. 2021;90:315–318.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34114269</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan M., Han S.C., Kelly S., Tamimi M., Giglio B., Lewis A. A case series of Guillain-Barré Syndrome After COVID-19 infection in New York. Neurol. Clin. Pract. 2021;11:e576–e578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8382418</ArticleId>
            <ArticleId IdType="pubmed">34484964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Civardi C., Collini A., Geda D.J., et al.  Antiganglioside antibodies in Guillain-Barré syndrome associated with SARS-CoV-2 infection. J. Neurol. Neurosurg. Psychiatry. 2020;91:1361–1362.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32859744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cutillo G., Saariaho A.-H., Meri S. Physiology of gangliosides and the role of antiganglioside antibodies in human diseases. Cell. Mol. Immunol. 2020;17:313–322.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7109116</ArticleId>
            <ArticleId IdType="pubmed">32152553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dufour C., Co T.K., Liu A. GM1 ganglioside antibody and COVID-19 related Guillain Barre syndrome - a case report, systemic review and implication for vaccine development. Brain Behav. Immun. Health. 2021;12</Citation>
        </Reference>
        <Reference>
          <Citation>Elf K., Askmark H., Nygren I., Punga A.R. Vitamin D deficiency in patients with primary immune-mediated peripheral neuropathies. J. Neurol. Sci. 2014;345(1–2):184–188.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25115500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Filosto M., Cotti Piccinelli S., Gazzina S., et al.  Guillain-Barre syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions. J. Neurol. Neurosurg. Psychiatry. 2021;92:751–756.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7650204</ArticleId>
            <ArticleId IdType="pubmed">33158914</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fragiel M., Miro O., Llorens P., et al.  Incidence, clinical, risk factors and outcomes of Guillain-Barre in COVID-19. Ann. Neurol. 2021;89:598–603.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33295021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gigli G.L., Bax F., Marini A., et al.  Guillain-Barré syndrome in the COVID-19 era: just an occasional cluster? J. Neurol. 2021;268:1195–1197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7236438</ArticleId>
            <ArticleId IdType="pubmed">32430572</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guilmot A., Slootjes S.M., Sellimi A., et al.  Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. J. Neurol. 2021;2021(268):751–757.</Citation>
        </Reference>
        <Reference>
          <Citation>Gutiérrez-Ortiz C., Méndez-Guerrero A., Rodrigo-Rey S., et al.  Miller fisher syndrome and polyneuritis cranialis in COVID-19. Neurology. 2020;95:e601–e605.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">32303650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keddie S., Pakpoor J., Mousele C., et al.  Epidemiological and cohort study finds no association between COVID-19 and Guillain-Barre syndrome. Brain. 2021;144:682–693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7799186</ArticleId>
            <ArticleId IdType="pubmed">33313649</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koike H., Katsuno M. Emerging infectious diseases, vaccines and Guillain-Barré syndrome. Clin. Exp. Neuroimmunol.. 2021 doi: 10.1111/cen3.12644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/cen3.12644</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kopscik M.R., Giourgas B.K., Presley B.C. A case report of acute motor and sensory polyneuropathy as the presenting symptom of SARS-CoV-2. Clin. Pract. Cases Emerg. Med. 2020;4:352–354.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7434291</ArticleId>
            <ArticleId IdType="pubmed">32926684</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lantos J.E., Strauss S.B., Lin E. COVID-19-associated miller fisher syndrome: MRI findings. Am. J. Neuroradiol. 2020;41:1184–1186.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7357656</ArticleId>
            <ArticleId IdType="pubmed">32467190</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lowery M.M., Taimur Malik M., Seemiller J., Tsai C.S. Atypical variant of Guillain Barre syndrome in a patient with COVID-19. J. Crit. Care Med. 2020;6:231–236.</Citation>
        </Reference>
        <Reference>
          <Citation>Maramattom B.V., Krishnan P., Paul R., et al.  Guillain-Barre syndrome following ChAdOx1-S/nCoV-19 vaccine. Ann. Neurol. 2021;90:312–314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">34114256</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Masuccio F.G., Barra M., Claudio G., Claudio S. A rare case of acute motor axonal neuropathy and myelitis related to SARS-CoV-2 infection. J. Neurol. 2021;268:2327–2330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7497229</ArticleId>
            <ArticleId IdType="pubmed">32940797</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Petrelli C., Scendoni R., Paglioriti M., Logullo F.O. Acute motor axonal neuropathy related to COVID-19 infection: a new diagnostic overview. J. Clin. Neuromuscul. Dis. 2020;22:120–121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7678351</ArticleId>
            <ArticleId IdType="pubmed">33214404</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rogawski E.T., Guertin K.A., Becker L., et al.  Assessment of seroprevalence of SARS-CoV-2 and risk factors associated with COVID-19 infection among outpatients in Virginia. JAMA Netw. Open. 2021;4</Citation>
        </Reference>
        <Reference>
          <Citation>Sevjar J.J., Baughman A.L., Wise M., Morgan O.W. Population incidence of Guillain-Barre syndrome: a systematic review and meta-analysis. Neuroepidemiology. 2011;36:123–133.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5703046</ArticleId>
            <ArticleId IdType="pubmed">21422765</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shapiro Ben David S., Potasman I., Rahamim-Cohen D. Rate of recurrent Guillain-Barré syndrome after mRNA COVID-19 vaccine BNT162b2. JAMA Neurol. 2021;78:1409–1411. doi: 10.1001/jamaneurol.2021.3287.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jamaneurol.2021.3287</ArticleId>
            <ArticleId IdType="pmc">PMC8411356</ArticleId>
            <ArticleId IdType="pubmed">34468703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stefanelli P., Bella A., Fedele G., et al.  Prevalence of SARS-CoV-2 IgG antibodies in an area of northeastern Italy with high incidence of COVID-19 cases: a population-based study. Clin. Microbiol. Infect. 2021;27:633.e1–633.e7.</Citation>
        </Reference>
        <Reference>
          <Citation>Wanleenuwat P., Iwanowski P., Kozubski W. Antiganglioside antibodies in neurological diseases. J. Neurol. Sci. 2019;408</Citation>
        </Reference>
        <Reference>
          <Citation>Webb A.J.S., Brain S.A.E., Wood R., Rinaldi S., Turner M.R. Seasonal variation in Guillain-Barre syndrome: a systematic review, meta-analysis, and Oxfordshire cohort study. J. Neurol. Neurosurg. Psychiatry. 2015;86(11):1196–1201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25540247</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
